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Abstract.  
Advances in the molecular segmentation of lung cancer has raised the possibility that 
neurotrophic tyrosine kinase receptor (NTRK) 1 fusions and NTRK1-3 expression may 
be promising molecular targets for future therapeutic interventions. To expand these 
findings and determine the prevalence of these mutations in a cohort of Japanese lung  
cancer  patients, we investigated the presence of NTRK1 fusions in surgical resection 
NSCLC samples (adenocarcinoma, 198 cases; and squamous cell carcinoma, 70 cases).  
Surprisingly, using reverse-transcription polymerase chain reaction (RT-PCR) and 
direct DNA sequencing, we were unable to identify fusions in any of those patients. We 
investigated  the antitumor effects of a selective pan-NTRK inhibitor, AZD7451, by 
evaluating its antiproliferative effects on the KM12 cell line (a colorectal cancer cell line 
harboring a tropomyosin-NTRK1 fusion) and the H460 and H810 cell lines [large-cell 
neuroendocrine carcinoma (LCNEC) cell lines expressing NTRK2]. Relative 
quantitative polymerase chain reaction (qPCR) was performed to measure the mRNA  
levels of the NTRK1-3 tyrosine kinase domain using cDNA extracted from KM12, H460 
and H810 cells. The cultures were grown in 6-well plates at a density of 1.0x10 6  
cell/well and treated with AZD7451 at different doses (1, 2.5, 4, 5, 7.5 and 10 nM) using 
dimethyl sulfoxide as a control. Following a 24-h incubation, the number of surviving  
cells was measured using a hemocytometer. Furthermore, we performed western 
blotting of the high‑affinity nerve growth factor receptor (TRKA) and NTRK2 (TRKB) 
proteins and monitored the effects on the downstream signaling pathways Akt and ERK 
in these cell lines following treatment with AZD7451 (KM12 and H460: 0, 1 and 5 nM; 
H810: 0 and 5 nM). Immunohistochemical analyses of the surgically resected samples  
were also performed, using anti-NTRK1,2 anti-bodies. We performed 
reverse-transcription PCR and direct sequencing to investigate NTRK fusions in 268 
patients; however, were unable to confirm the presence of NTRK fusions in this cohort. 
Further immunohistochemical analyses of the primary patient samples demonstrated 
that none of 61 tumors had NTRK1 overexpression and 7 of 39 samples exhibited 
NTRK2 expression, including 1 LCNEC sample. The qPCR results from the KM12 cell 
line revealed an apparent increase and overexpression of NTRK1 mRNA levels, while 
H460 cells exhibited a modest increase and the H810 cell line showed no apparent 
increase in the expression of any NTRK1-3 isoforms. There were no increases in the 
NTRK2 mRNA levels in any of the three cell lines, although KM12 and H460 cells 
exhibited low levels of NTRK2 expression. In vitro growth and prolif-eration of the 
KM12 cell line harboring the NTRK1-fusion was  found  to  be  potently  inhibited  
by  AZD7451  at  a concentration of 2 nM. The proliferation of H460 cells was also 
found to be inhibited at a concentration of 5 nM, while there was no apparent inhibitory 
effect of AZD7451 on the growth or proliferation of H810 cells. Western blotting of 
KM12 cells treated with AZD7451 also revealed a potent inhibition of TRKA 
phosphorylation following AZD7451 treatment. Analysis of H460 cells confirmed the 
expression and inhibition of phosphorylation of NTRK2, whereas there was little to no 
expression of TRKA/B in H810 cells. Subsequent in vitro analysis of cell lines treated 
with the pan-TRK inhibitor AZD7451 suggested that the proliferation of KM12 and 
H460 cells was significantly inhibited by AZD7451, while H810 cells expressing low 
levels of wild-type NTRK1-3 were not inhibited. Based on these results, there is 
potential for a NTRK-dependent proliferation driver in a subpopulation of lung cancer 
patients with NTRK expression. In addition, pharmacological inhibition with a NTRK 
inhibitor, such asAZD7451, in cells harboring NTRK1 fusions, may be associated with 
beneficial antitumor effects. 
